Tianjin TEDA Biomedical Engineering (8189) Stock Overview
Engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for 8189 from our risk checks.
8189 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Tianjin TEDA Biomedical Engineering Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.41 |
| 52 Week High | HK$0.65 |
| 52 Week Low | HK$0.069 |
| Beta | 0.12 |
| 1 Month Change | 0% |
| 3 Month Change | -13.83% |
| 1 Year Change | 432.89% |
| 3 Year Change | 117.74% |
| 5 Year Change | 486.96% |
| Change since IPO | -32.50% |
Recent News & Updates
Recent updates
Some Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shareholders Look For Exit As Shares Take 29% Pounding
Apr 07
Subdued Growth No Barrier To Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) With Shares Advancing 55%
Jan 17Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Stock Rockets 38% As Investors Are Less Pessimistic Than Expected
Dec 02There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 73% Price Jump
Oct 17There's Reason For Concern Over Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) Massive 38% Price Jump
Aug 16Tianjin TEDA Biomedical Engineering Company Limited's (HKG:8189) 26% Share Price Plunge Could Signal Some Risk
May 07Is Tianjin TEDA Biomedical Engineering (HKG:8189) Weighed On By Its Debt Load?
Sep 12Investors Give Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189) Shares A 28% Hiding
Apr 17Is Tianjin TEDA Biomedical Engineering (HKG:8189) A Risky Investment?
Apr 07Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Nov 01Tianjin TEDA Biomedical Engineering (HKG:8189) Is Making Moderate Use Of Debt
Apr 21Is Tianjin TEDA Biomedical Engineering (HKG:8189) Using Too Much Debt?
Oct 26Tianjin TEDA Biomedical Engineering (HKG:8189) Has Debt But No Earnings; Should You Worry?
Apr 06Health Check: How Prudently Does Tianjin TEDA Biomedical Engineering (HKG:8189) Use Debt?
Dec 22
Shareholder Returns
| 8189 | HK Chemicals | HK Market | |
|---|---|---|---|
| 7D | 3.8% | -2.2% | -1.8% |
| 1Y | 432.9% | 7.8% | 22.1% |
Return vs Industry: 8189 exceeded the Hong Kong Chemicals industry which returned 7.8% over the past year.
Return vs Market: 8189 exceeded the Hong Kong Market which returned 22.1% over the past year.
Price Volatility
| 8189 volatility | |
|---|---|
| 8189 Average Weekly Movement | 7.7% |
| Chemicals Industry Average Movement | 6.3% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 8189 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8189's weekly volatility has decreased from 19% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 260 | Li Sun | bioteda.com |
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China. It operates through two segments: Fertiliser Products, and Elderly Care and Health Care Services. The company’s biological compound fertilizer products include active fertilizer, mixture with nitrogen, phosphorus, and potassium with various formulas that are used for the facilitation of balanced growth of grains, fruits, and vegetables.
Tianjin TEDA Biomedical Engineering Company Limited Fundamentals Summary
| 8189 fundamental statistics | |
|---|---|
| Market cap | HK$864.23m |
| Earnings (TTM) | -HK$32.45m |
| Revenue (TTM) | HK$421.89m |
Is 8189 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8189 income statement (TTM) | |
|---|---|
| Revenue | CN¥385.48m |
| Cost of Revenue | CN¥368.51m |
| Gross Profit | CN¥16.97m |
| Other Expenses | CN¥46.62m |
| Earnings | -CN¥29.65m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 4.40% |
| Net Profit Margin | -7.69% |
| Debt/Equity Ratio | 533.6% |
How did 8189 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/21 20:29 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tianjin TEDA Biomedical Engineering Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.